Dimerix (ASX:DXB) completed the second part of recruitment for its phase 3 kidney disease trial investigating the use of the DMX-200 in patients with focal segmental glomerulosclerosis, a form of kidney disease, according to a Tuesday filing with the Australian bourse.

The study, named DMX-200 Action3, recruited its 144th patient, effectively completing 50% of the total recruitment for the trial, the filing said. Patients were randomized and dosed with either the medication or placebo over 35 weeks.

The company expects to complete the recruitment of all 286 adult patients in the third quarter of 2025, the filing said.

The company's shares slipped almost 1% in recent Tuesday trade.